Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page
- CheckyesterdayChange DetectedA new document revision, Revision: v3.5.4, was added to the study record, replacing Revision: v3.5.3. This update indicates an updated version of the study protocol and related documentation.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision: v3.5.3 was added and Revision: v3.5.2 was removed. This indicates a minor version update to the page rather than a change to the study details.SummaryDifference0.0%

- Check30 days agoChange DetectedVersion bumped from 3.5.0 to 3.5.2.SummaryDifference0.0%

- Check59 days agoChange DetectedNaples, Italy, 80131 has been added as a study location and Napoli, Italy, 80131 removed; the study revision version updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check73 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check95 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. This is a metadata version change and does not alter the study details displayed.SummaryDifference0.0%

Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.